Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 3
2014 2
2015 1
2017 1
2018 3
2019 1
2020 3
2021 3
2022 5
2023 4
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hoeper compare (20 results)?
Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies.
Hoeper MM, Rosenkranz S, Badesch DB, Humbert M, Langleben D, McConnell JW, Hegab S, Rahner C, Richard JF, Ghofrani HA. Hoeper MM, et al. Respir Med. 2025 Jan;236:107910. doi: 10.1016/j.rmed.2024.107910. Epub 2024 Dec 10. Respir Med. 2025. PMID: 39667586 Free article.
At PATENT-1 Week 12, improvements in COMPERA 2.0 risk strata and median 6-min walk distance were seen with riociguat vs placebo in patients assessed as intermediate-low risk and intermediate-high risk at baseline by COMPERA 2.0. More patients improved their COMPE
At PATENT-1 Week 12, improvements in COMPERA 2.0 risk strata and median 6-min walk distance were seen with riociguat vs placebo in pa …
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.
Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV. Rosenkranz S, et al. J Heart Lung Transplant. 2025 Feb;44(2):135-146. doi: 10.1016/j.healun.2024.08.018. Epub 2024 Sep 3. J Heart Lung Transplant. 2025. PMID: 39236972 Free article.
Safety, efficacy (6-minute walk distance [6MWD], World Health Organization functional class [WHO-FC], and N-terminal probrain natriuretic peptide [NT-proBNP]), and COMPERA 2.0 risk status were assessed in patients with 0, 1 to 2, or 3 to 4 cardiometabolic comorbidities (ob …
Safety, efficacy (6-minute walk distance [6MWD], World Health Organization functional class [WHO-FC], and N-terminal probrain natriuretic pe …
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
Benza RL, Simonneau G, Ghofrani HA, Corris PA, Langleben D, Rosenkranz S, White RJ, Cheng CC, Campos FTAF, Kim HK, Souza R, Chang M, Rahner C, Meier C, Hoeper MM. Benza RL, et al. J Heart Lung Transplant. 2024 Oct;43(10):1756-1760. doi: 10.1016/j.healun.2024.06.002. Epub 2024 Jun 7. J Heart Lung Transplant. 2024. PMID: 38852934 Free article. Clinical Trial.
This post hoc study applied the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 and Comparative Prospective Registry of Newly Initiated Therapies for Pulmonary (COMPERA) 2.0 risk-assessment tools to REPLACE to investigate the impact of basel …
This post hoc study applied the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 and Comparative Prospective …
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
McLaughlin V, Alsumali A, Liu R, Klok R, Martinez EC, Nourhussein I, Bernotas D, Chevure J, Pausch C, De Oliveira Pena J, Lautsch D, Hoeper MM. McLaughlin V, et al. Adv Ther. 2024 Jan;41(1):130-151. doi: 10.1007/s12325-023-02684-x. Epub 2023 Oct 18. Adv Ther. 2024. PMID: 37851297 Free PMC article.
Risk stratum-adjusted mortality and lung/heart-lung transplant probabilities were based on COMPERA PAH registry data, and the post-transplant mortality probability was obtained from existing literature. ...
Risk stratum-adjusted mortality and lung/heart-lung transplant probabilities were based on COMPERA PAH registry data, and the post-tr …
Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.
Pausch C, Pittrow D, Hoeper MM, Huscher D. Pausch C, et al. Eur Respir J. 2023 Nov 29;62(5):2301023. doi: 10.1183/13993003.01023-2023. Print 2023 Nov. Eur Respir J. 2023. PMID: 37802633 Free PMC article.
The 4-strata model was developed from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) and cross-validated by the French PH Registry [3, 4]. Both studies included patients when all three variables, i.e. ...
The 4-strata model was developed from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMP
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
Distler O, Ofner C, Huscher D, Jordan S, Ulrich S, Stähler G, Grünig E, Held M, Ghofrani HA, Claussen M, Lange TJ, Klose H, Rosenkranz S, Vonk-Noordegraaf A, Vizza CD, Delcroix M, Opitz C, Pausch C, Scelsi L, Neurohr C, Olsson KM, Coghlan JG, Halank M, Skowasch D, Behr J, Milger K, Remppis BA, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Wilkens H, Pittrow D, Hoeper MM, Ewert R. Distler O, et al. Rheumatology (Oxford). 2024 Apr 2;63(4):1139-1146. doi: 10.1093/rheumatology/kead360. Rheumatology (Oxford). 2024. PMID: 37462520 Free PMC article.
We sought to assess contemporary treatment patterns and survival of patients with various forms of CTD-PAH. METHODS: We analysed data from COMPERA, a European pulmonary hypertension registry, to describe treatment strategies and survival in patients with newly diagnosed PA …
We sought to assess contemporary treatment patterns and survival of patients with various forms of CTD-PAH. METHODS: We analysed data from …
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.
Rosenkranz S, Pausch C, Coghlan JG, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Delcroix M, Ghofrani HA, Ewert R, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Scelsi L, Neurohr C, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Remppis BA, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Lange TJ, Olsson KM, Hoeper MM, Opitz C. Rosenkranz S, et al. J Heart Lung Transplant. 2023 Jan;42(1):102-114. doi: 10.1016/j.healun.2022.10.003. Epub 2022 Oct 13. J Heart Lung Transplant. 2023. PMID: 36333206 Free article.
It is unknown to what extent the presence of these comorbidities affects the response to PAH therapies and whether risk stratification predicts outcome in patients with comorbidities. METHODS: We assessed the database of COMPERA, a European pulmonary hypertension registry, …
It is unknown to what extent the presence of these comorbidities affects the response to PAH therapies and whether risk stratification predi …
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Park DH, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Lange TJ, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Swift AJ, Thompson AAR, Elliot CA, Rosenkranz S, Condliffe R, Kiely DG, Halank M. Hoeper MM, et al. Lancet Respir Med. 2022 Oct;10(10):937-948. doi: 10.1016/S2213-2600(22)00097-2. Epub 2022 Jun 28. Lancet Respir Med. 2022. PMID: 35777416 Free PMC article.
While 99 (77%) patients in COMPERA and 133 (72%) patients in ASPIRE with classical IPAH were female, there was a lower proportion of female patients in the IPAH and a lung phenotype cohort (95 [35%] COMPERA; 75 [54%] ASPIRE), which was similar to group 3 pulmonary h …
While 99 (77%) patients in COMPERA and 133 (72%) patients in ASPIRE with classical IPAH were female, there was a lower proportion of …
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Rosenkranz S, Lange TJ. Hoeper MM, et al. J Heart Lung Transplant. 2022 Jul;41(7):971-981. doi: 10.1016/j.healun.2022.03.011. Epub 2022 Mar 22. J Heart Lung Transplant. 2022. PMID: 35430147 Free article.
BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of treatments for pulmonary arterial hypertension (PAH) needs to be further investigated. METHODS: Using the COMPERA database, we evaluated the prognostic value of improvements …
BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of treatments for pulmonary arterial hypert …
29 results